Recent News

Constellation Brands to Invest $100 Million in Women-Led Start-Ups by 2028

Thursday, December 06

VICTOR, N.Y., Dec. 6, 2018 -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that Constellation Brands Ventures (CBV), the company’s corporate venture capital group, intends to invest $100 million in female-founded or female-led businesses in the beverage alcohol space and adjacent categories by 2028 through a new program, Focus on Female Founders. The company has completed its first investments in two specialty beverage companies: Austin Cocktails and Vivify Beverages.

Read More

PICKUP Picks up $5 Million in Funding

Tuesday, November 13

DALLAS — Pickup, an Uber-like last-mile delivery service for furniture and other large items, has completed a $5 million round of venture capital funding that will speed up expansion of its operations including entry into new markets.

Read More

Here's how Pittsburgh investors scored when Expedia bought a Chicago startup

Wednesday, November 07

Expedia Group’s $21.5 million acquisition of Chicago-based ApartmentJet Inc. translates into a windfall for angel investors in Pittsburgh.

BlueTree Venture Fund and BlueTree Allied Angels will realize a 4.3 times return on its combined $450,000 investment in less than a year, said Catherine Mott, founder, CEO and managing partner of 15-year-old Wexford-based BlueTree Capital Group LLC.

Read More

Expedia Group Acquires Pillow and ApartmentJet to Enhance Its Alternative Accommodations Marketplace for Residents, Owners and Managers in Urban Markets

Monday, October 29

BELLEVUE, Wash., Oct. 25, 2018 /PRNewswire/ -- Expedia Group, Inc. (NASDAQ: EXPE) announced today the acquisitions of Pillow, a software solution that helps building owners and managers empower their long-term residents to rent their residences, and ApartmentJet, a software solution enabling the rental of guest suites in multifamily communities. Acquiring Pillow and ApartmentJet will help unlock urban growth opportunities that, over time, will contribute to HomeAway's ability to add an even broader selection of accommodations to its marketplace and marketplaces across Expedia Group brands, ensuring travelers always find the perfect place to stay.

Read More

Cognition Therapeutics to Sponsor Third International Symposium on Sigma-2 Receptors: Role in Health and Disease during the Society for Neuroscience Annual Meeting

Wednesday, October 24

Pittsburgh, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic protection and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced its sponsorship of the Third International Symposium on Sigma-2 Receptors: Role in Health and Disease.

Read More

PECA Labs' exGraft Helps Save Lives -- Case Report

Friday, October 12

Just a few weeks ago, an infant boy’s life was saved by a surgeon using the PECA Labs exGraft. Between the mundanity of regulatory compliance and supply-chain management, it could be easy to lose sight of the ultimate impact of our work.

Read More

Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant for Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease

Tuesday, October 02

Pittsburgh, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a multiyear grant expected to total $16.6 million to support the Phase 2 SHINE study of Elayta™ (CT1812).

Read More

Cognition Therapeutics Presents Additional Elayta™ Clinical Results during Alzheimer's Association International Conference (AAIC) Symposium Session

Monday, July 23

Pittsburgh, July 23, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurodegenerative disorders, today announced that co-founder and Chief Science Officer Susan Catalano, Ph.D. presented additional findings supporting the unique synaptorestorative mechanism of action of Elayta™ (CT1812), Cognition’s lead candidate for the treatment of mild-to-moderate Alzheimer’s disease, at the Alzheimer's Association International Conference (AAIC) in Chicago. Dr. Catalano was invited by the Association to present these results as part of the July 23rd Symposium Session: Translational Research In Reality - What Are The Criteria From Concept To Clinic?

Read More